Our People

Management Team

H Daniel Perez MD

H Daniel Perez MD
Co-Founder, CEO and Chairman

During his twenty-four years in the pharmaceutical industry, Dr Perez has developed wide-ranging experience driving R&D operations, clinical trials, collaborations, licensing deals, spin-outs and acquisitions. He has published extensively and has been elected to multiple scientific societies and Boards.

Read More

H Daniel Perez MD co-founded Naia Rare Diseases and currently serves as Chairman and Chief Executive Officer.

Prior to that, he was a venture partner at Bay City Capital. Earlier in his career, he was president and chief executive officer of Berlex Biosciences (the U.S. arm of Schering AG). He led R&D efforts in the United States, Berlin and Kobe, initiated multiple clinical trials, and oversaw the execution of numerous collaborations, licensing deals, spin-outs and acquisitions until he left the company upon its acquisition by Bayer. Dr. Perez has published extensively and has been elected to multiple scientific societies and nominated to the National Academy of Sciences.

Dr. Perez serves on the Board of Directors of Presidio Pharmaceuticals and Celtaxsys, on the Scientific Advisory Board of Cardium, on the Investment Board of Glaxo GSK, China and on the President’s Council for the Gladstone Institutes at the University of California, San Francisco (UCSF). Previously, he was a member of the Board of Directors of BayBio, Cleveland Biolabs and Hyperion Therapeutics.

He received his medical degree in Buenos Aires, Argentina. He completed his medical training at Beth Israel-Mount Sinai in New York and a fellowship in rheumatology and immunology at New York University. He served on the faculty at New York University as an assistant professor of medicine and at UCSF as a professor of medicine before joining the pharmaceutical industry.

Mark Bagnall

Mark Bagnall
Co-Founder, CFO and COO

Mr Bagnall has held c-suite positions in public and private biotechnology companies for more than 20 years. During that time, he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings and negotiated numerous licensing agreements.

Read More

Mark Bagnall co-founded Naia Rare Diseases and currently serves as Chief Financial Officer, Chief Operating Officer and a Director.

He has held senior management positions in public and private biotechnology companies for more than 20 years. During that time he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings, and negotiated numerous licensing agreements.

Prior to founding Naia, he served as president, chief executive officer and a member of the Board of Directors of GenturaDx until its successful sale to Luminex Corporation. GenturaDx was a BVI-based molecular diagnostics company with operations in Shanghai, China and the San Francisco Bay Area.  Before joining GenturaDx, Mr Bagnall was executive vice president and a member of the Board of ADVENTRX Pharmaceuticals. Prior to ADVENTRX, he was senior vice president at Metabolex, Inc., where he raised more than $100 million Before Metabolex, Mr Bagnall was chief financial officer of several public and private biotechnology companies and was responsible for many public and private financings, mergers and licensing transactions.

Mr Bagnall was one of the founders the Association of Bioscience Financial Officers, an international organization of life science CFOs. He serves on the Board of Directors of Ativa Medical Corporation is an advisor to the Board of Fluoresentric, Inc. Previously, he served on the Boards of ADVENTRX Pharmaceuticals and VIA Pharmaceuticals. He is a CPA and started his career in the high technology/biotechnology practice of Ernst & Young.

Advisory Board

Mark Pimentel MD FRCPC

Chairman of the Naia Rare Diseases Advisory Board; Director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai Medical Center.

Mark DeLegge MD FACG CNSP AGAF FASGE

Medical University of South Carolina in Charleston

John DiBaise MD

Professor of Medicine, Mayo Clinic, Scottsdale

Stuart Kaufman MD

Medical Director, Pediatric Transplantation, Georgetown Medical Center

Farooq Rahman BSc PhD FRCP

Consultant Gastroenterologist & Lead Physician for Intestinal Failure, University College Hospital, London

Prof Palle Bekker Jeppesen MD PhD

Head of Research at the Department of Gastroenterology, Rigshospitalet, Copenhagen

Market Advisor

Mark Cicacci

Formerly Regional Business Director, Rare Disease – Shire and NPS

Patient/Physician Relations

Andrew Jablonski

CEO, Short Bowel Syndrome Foundation

Contact us for further information